This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - Agenda XML Reports
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AF97 Publication ID: Fall 2013 
Title: Abbreviated New Drug Applications and 505(b)(2) Applications 
Abstract: This proposed rule would make changes to certain procedures for Abbreviated New Drug Applications and 505(b)(2) applications relating to patent certifications, provision of notice to patent owners and application holders, the availability of a 30-month stay of approval, amendments and supplements and the types of bioavailability and bioequivalence data that can be used to support these applications. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Undetermined  Unfunded Mandates: No 
CFR Citation: 21 CFR 314.3    21 CFR 314.50    21 CFR 314.52    21 CFR 314.53    21 CFR 314.54    21 CFR 314.60    21 CFR 314.70    21 CFR 314.90    21 CFR 314.93    21 CFR 314.94    21 CFR 314.95    21 CFR 314.96    21 CFR 314.97    21 CFR 314.99    21 CFR 314.101    21 CFR 314.105    21 CFR 314.107    21 CFR 314.108    21 CFR 314.125    21 CFR 314.127    21 CFR 320.1    21 CFR 320.23   
Legal Authority: PL 108-173, title XI    21 USC 355    21 USC 371   
Legal Deadline:  None
Action Date FR Cite
NPRM  11/00/2013 
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: None 
Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Janice L. Weiner
Senior Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research, Building 51, Room 6268, 10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Phone:301 796-3601
Fax:301 847-8440

About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us